Study type: Human research · Status: Verified against declared source
Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment
2024
Study scale: It was independently extracted by 2 researchers (M.W.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Currently, confirmed effective treatments for early recanalization in AIS primarily encompass intravenous thrombolysis and endovascular therapy.[3] The prompt reopening of obstructed vessels serves to salvage the ischemic penumbra.
Methods
It was independently extracted by 2 researchers (M.W.
Scale or participants
It was independently extracted by 2 researchers (M.W.
Key findings
This study conducts a rapid health technology assessment to systematically evaluate the effectiveness, safety, and cost-effectiveness of Cerebrolysin as an adjunctive therapy for acute ischemic stroke to provide evidence-based medicine for clinical decisions of Cerebrolysin.
Limitations and uncertainty
Currently, confirmed effective treatments for early recanalization in AIS primarily encompass intravenous thrombolysis and endovascular therapy.[3] The prompt reopening of obstructed vessels serves to salvage the ischemic penumbra.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.